The analysis of inflammatory and immune cell populations revealed that the percentage of CD3+/CD4+, CD3+/CD8+, CD3+/NK1.1+ T lymphocytes, natural killer T lymphocyte subsets, and CD3-/B220+ B lymphocytes were unchanged in TMI-5-treated DLD1 tumors (Supplementary Figure S1A–D) while CD11b+/F4-80+ macrophages and CD11b+/F4-80+/CD68+ tumor-associated macrophages (TAM) were decreased (Figure 3I). The gene discussed is CD68; the disease is neoplasm.